[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643428":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":18,"locations":26,"responsibleParty":67,"collaborators":10,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":10,"eligibilityCriteria":74,"healthyVolunteers":71,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":10,"studyType":81,"phases":10,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":92,"whyStopped":10,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Odense University Hospital","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients enrolled in a Treat@Home study",null,"Patients who are enrolled in one of the two Treat@Home studies will be invited to participate",{"label":13,"type":10,"description":14,"interventionNames":10},"Patients declining enrollment in a Treat@Home study","Patients who are invited in one of the two Treat@Home studies but decline this invitation will be invited to participate",{"label":16,"type":10,"description":17,"interventionNames":10},"Patients deemed not eligible for enrollment in a Treat@Home study","Patients deemed not eligible for enrollment in one of the two Treat@Home studies will be invited for enrollment",[19,24],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Jannie Kirkegaard, RN","CONTACT","+45 29648494","jannie.kirkegaard@rsyd.dk",{"name":25,"role":21,"phone":10,"phoneExt":10,"email":10},"Kristina Nørskov, RN, PhD",[27,44,54],{"facility":28,"status":10,"city":29,"state":10,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Copenhagen University Hospital (Rigshospitalet)","Copenhagen","2100","Denmark","DK",{"type":34,"coordinates":35},"Point",[36,37],12.56553,55.67594,{"lat":37,"lon":36},[40],{"name":41,"role":21,"phone":42,"phoneExt":10,"email":43},"Iben Husted Nielsen, Post. Doc","+45 26227757","iben.husted.nielsen@regionh.dk",{"facility":5,"status":10,"city":45,"state":10,"zip":46,"country":31,"countryCode":32,"cosmosGeoPoint":47,"geoPoint":51,"contacts":52},"Odense","5000",{"type":34,"coordinates":48},[49,50],10.38831,55.39594,{"lat":50,"lon":49},[53],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},{"facility":55,"status":10,"city":56,"state":10,"zip":57,"country":31,"countryCode":32,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Sjællands Universitets Hospital","Roskilde","4000",{"type":34,"coordinates":59},[60,61],12.08035,55.64152,{"lat":61,"lon":60},[64],{"name":25,"role":21,"phone":65,"phoneExt":10,"email":66},"+45 22648697","knors@regionsjaelland.dk",{"type":68,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100643428","why-patients-decline-or-are-being-deemed-ineligible-to-receive-home-based-treatment-a-mixed-methods-study-100643428",false,"NCT07634263","Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study","Inclusion Criteria:\n\n* \\>=18 years old\n* diagnosed Multiple Myeloma or acute leukemia, and recieving treatment with either Daratumumab or Cytarabine.\n\nExclusion Criteria:\n\n\\- Dementia, psychotic disorders, or other cognitive impairments limiting participation.","ALL","18 Years","100 Years",{"count":79,"type":80},50,"ESTIMATED","OBSERVATIONAL","Treatment for blood cancers has improved significantly, and more patients are now living longer. However, these treatments are often intensive and long-lasting, and many patients experience serious side effects and symptoms. As more patients require ongoing treatment and long-term care, the demand for haematology services is increasing.\n\nHome-based treatment is expected to play an increasingly important role in the future. It can support more patient-centred care, help patients maintain their everyday lives, improve quality of life, and reduce pressure on hospitals. Despite these benefits, some patients are either not eligible for home-based treatment or choose to decline it. The reasons for this are not yet well understood.\n\nThis study combines quantitative data-such as medical information, sociodemographic characteristics, and questionnaire responses about quality of life and health literacy-with qualitative interviews involving patients, relatives, and healthcare professionals. The aim is to identify barriers and differences between patients, and to better understand why some patients opt out of or are unable to participate in home-based treatment.\n\nThe findings will help support the development of more inclusive and patient-centred care models, ensure more equal access to home-based treatment, and improve support for socially vulnerable patients. The results will be shared with patients and families through patient organisations, with hospitals through the Treat@Home programme, and at national and international conferences.",[84,85,86],"Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma","Multiple Myeloma Progression","Multiple Myeloma Refractory",[88,89,90,91],"Hematologic Neoplasms","multiple myeloma","Home Care Services","Patient Acceptance of Health Care","NOT_YET_RECRUITING","2026-06-03",{"date":95,"type":96},"2026-06-08","ACTUAL",{"date":98,"type":80},"2026-07-01",{"date":100,"type":80},"2028-06-30",{"name":5,"class":6},3]